Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning

In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's NVO Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of blocked intestines following its use. 

This alteration follows a series of FDA-approved updates for the product's manufacturer, Novo Nordisk.

The change in Ozempic's label aligns it with other medications in the GLP-1 agonist class, such as Novo Nordisk's Wegovy and Eli Lilly And Co's LLY Mounjaro. 

Novo Nordisk and Eli Lilly are facing a lawsuit related to claims that their medications can lead to a similar condition known as gastroparesis, characterized by stomach paralysis and a blockage in the passage of food to the small intestine despite no physical obstruction.

All these drugs now acknowledge the increased reports of ileus, a condition characterized by a blockage in the intestines.

Novo Nordisk and Eli Lilly are facing a lawsuit related to claims that their medications can lead to a similar condition known as gastroparesis, characterized by stomach paralysis and a blockage in the passage of food to the small intestine despite no physical obstruction.

The FDA has not directly attributed this potentially life-threatening condition to the use of these drugs. 

According to the label, "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure."

The FDA's database reveals 8,571 reports of gastrointestinal disorders associated with semaglutide medications, including Ozempic and Wegovy, CBS noted.

Among these reports, 33 specifically mention ileus as a reaction, with two cases resulting in fatalities.

Price Action: NVO shares are down 0.27% at $91.54 on the last check Wednesday.